HCN News Team – Page 239 – Highly Capitalized

Saturday, September 26, 2026 We Follow The Money.

About HCN News Team

The News Team at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Optimi Health Obtains Key Amendment to Dealer’s Licence

HCN News Team2023-11-27T19:08:11-08:00November 27th, 2023|Insights|

LOS ANGELES- Optimi Health, a Canadian company specializing in psychedelic ...

Germany Amends Cannabis Legalization Bill, Balancing Reform and Regulation

HCN News Team2023-11-27T19:07:00-08:00November 27th, 2023|World|

BERLIN- German lawmakers have significantly revised the country's cannabis ...

Psyence Group Inc. Announces Resignation of Board Member Marvin Singer

HCN News Team2023-11-26T17:00:59-08:00November 26th, 2023|Insights|

LOS ANGELES- Psyence Group Inc a clinical-stage life science biotechnology ...

Compass Pathways Launches UK Phase of Landmark Psilocybin Study for Treatment-Resistant Depression

HCN News Team2023-11-26T16:57:50-08:00November 26th, 2023|Capital|

NEW YORK- Compass Pathways plc (Nasdaq: CMPS), a biotechnology leader ...

Alabama Medical Cannabis Commission Settles Lawsuits

HCN News Team2023-11-26T16:44:44-08:00November 26th, 2023|Policy|

LOS ANGELES- The Alabama Medical Cannabis Commission (AMCC) has made ...

Swedish Researchers Use Psychedelics to Explore Brain Function and AI Development

HCN News Team2023-11-26T16:43:46-08:00November 26th, 2023|Insights|

LOS ANGELES- In a groundbreaking study at Lund University in ...

Minnesota Tests New Saliva-Based Roadside Cannabis Impairment Assessment

HCN News Team2023-11-26T16:41:55-08:00November 26th, 2023|Policy|

LOS ANGELES- In a groundbreaking move, Minnesota's Office of Traffic ...

New York and Missouri’s Contrasting Cannabis Market Progress in 2023

HCN News Team2023-11-23T21:17:43-08:00November 23rd, 2023|Capital|

NEW YORK- In a striking contrast of cannabis market development, ...

Cybin Inc. Secures $30 Million in Funding to Advance Psychedelic Treatment Research

HCN News Team2023-11-23T21:11:48-08:00November 23rd, 2023|Capital|

NEW YORK- Toronto-based Cybin Inc., a clinical-stage biopharmaceutical company, has ...

Clearmind Medicine Inc. Announces Reverse Share Split to Comply with Nasdaq Regulations

HCN News Team2023-11-23T21:10:28-08:00November 23rd, 2023|Insights|

NEW YORK- Clearmind Medicine Inc., a biotech company renowned for ...

Previous 238239240 Next

DISCLAIMER NOTE: This email should be considered strictly private and confidential. Sender of this email is not a United States Securities Dealer, nor Broker, nor U.S. Investment Adviser. Sender is a Registered Corporation and Consultant, and makes no warranties, nor representations as to the buyer, seller, or transaction. Furthermore, this email includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Read more

HCN Media Group | 171 Pier Avenue, Suite 177, Santa Monica, California, 90405

© Copyright | Highly Capitalized | All Rights Reserved | Website by Vadimages.